Ozempic label, AccessFDA Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system, Frontiers in Public Health (2022) Gastrointestinal tolerability of onceweekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss, Diabetes, Obesity, and Metabolism (2021) Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss, JAMA Network (2023) Constipation, Penn State College Medicine Foods for constipation, Johns Hopkins Medicine Exercise therapy in patients with constipation: A systematic review and meta-analysis of randomized controlled trials, Scandinavian Journal of Gastroenterology (2019) Bowel retraining, National Library of Medicine (2022) Concerned about constipation
As we age, our natural production of Growth Hormone enters a clinical decline known as Somatopause
Some practitioners have explored microdosing GLP-1 for autoimmune conditions , where the anti-inflammatory properties of GLP-1 receptor activation are the primary goal rather than weight loss
Some researchers also explore combining GLP-1 therapy with other weight loss peptide stacks to enhance results, though this should only be done under medical supervision
